FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...
Three years ago, Maurice Blake was diagnosed with prostate cancer. "I didn't have any of the traditional symptoms, apart from ...
By Puyaan Singh and Sahil Pandey March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ...
Prostate tumors contain more microplastics than healthy prostate tissue, researchers from New York University Langone Health ...
Scientists at NYU Langone Health examined cancerous and benign tissues from 10 patients with prostate cancer and found “small fragments of plastic” in both — but the tumors had much higher ...
ADT with leuprolide was tied to increased coronary plaque vs relugolix in prostate cancer. What does this mean for CV risk?
One type of androgen deprivation therapy may speed coronary plaque growth in men being treated for localized prostate cancer.
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
Men with prostate cancer are being denied NHS access to a treatment used by Lord Cameron, a senior doctor has revealed.
Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results